| 66199 | |
| Hospital-acquired (nosocomial) infections cause or contribute to 99,000 deaths each year in the United States alone. A patient's weakened state combined with bacteria's increasing resistance to antibiotics makes these infections difficult to treat. The current suite of antibiotics available for treating serious nosocomial infections, such as MRSA, can have unwanted side effects; hence, it is important to identify new antibiotics. Researchers at Purdue University have developed a class of antibiotic compounds designed to specifically target common nosocomial infections. By selectively targeting the mevalonate pathway of Gram-positive bacteria, these compounds will be more effective with fewer side effects. Several of the analogues also demonstrated selective antibacterial activity against MRSA and VRE, two of the most common and most dangerous nosocomial infections. Advantages: -Targets common nosocomial infections -Fewer side effects Potential Applications: -Medical/Healthcare -Pharmaceutical Industry -Drug Development |
|
|
|
|
May 8, 2015
CON-Patent
United States
9,604,925
Mar 28, 2017
Mar 15, 2013
Utility Patent
United States
9,073,832
Jul 7, 2015
Apr 24, 2012
Provisional-Patent
United States
(None)
(None)
Apr 23, 2012
Provisional-Patent
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |